Background: We sought to determine whether extended-spectrum b-lactamases (ESBLs) and AmpC blactamases (derepressed and inducible), alone and in combination, could be detected in unidentified members of the Enterobacteriaceae using a simple, overnight disc diffusion test.
Introduction
Members of the Enterobacteriaceae commonly express plasmid-encoded b-lactamases (e.g. TEM-1, TEM-2, SHV-1) that confer resistance to penicillins, but not to cephalosporins with oxyimino side chains.
Resistance to these extended-spectrum cephalosporins appeared initially in a limited number of genera (Enterobacter cloacae, Citrobacter freundii, Serratia marcescens and Morganella morganii) that could hyper-produce AmpC b-lactamases. Such b-lactamases are typically encoded on the chromosome where their expression may be inducible. When induced or derepressed, they hydrolyse cephamycins (cefoxitin and cefotetan) as well as third-generation cephalosporins (cefotaxime, ceftriaxone and ceftazidime) and monobactams (aztreonam) but are poorly inhibited by b-lactamase inhibitors such as clavulanic acid. 1 In the mid-1980s, 2 extended-spectrum b-lactamases (ESBLs) emerged. These evolved via point mutations of TEM-1, TEM-2 and SHV-1 genes and were capable of hydrolysing thirdgeneration cephalosporins and monobactams. In contrast to AmpC b-lactamases, they are not active against cephamycins but are susceptible to b-lactamase inhibitors (e.g. clavulanic acid). 1 These mutant enzymes were most often found in nosocomial Klebsiella spp. from patients in intensive care or other specialist settings.
From 2000 onwards, however, CTX-M ESBLs began to predominate, mainly in Escherichia coli and predominantly at the hospital/community interface. These enzymes generally have greater activity against cefotaxime than other oxyimino-b-lactam substrates and represent the escape and mutation of chromosomal b-lactamases from Kluyvera spp. 3 Recent concern focuses on AmpC b-lactamases in E. coli and Klebsiella pneumoniae. The former can hyper-produce its chromosomal AmpC b-lactamase, which is normally only present at low levels. More alarmingly, both can acquire AmpC b-lactamases on plasmids.
Current advice is to screen for ESBL production using both cefotaxime and ceftazidime, or to use cefpodoxime, and to carry out confirmatory tests on resistant isolates. 4 Techniques for confirming ESBL production all depend on detecting synergy between clavulanic acid and the indicator cephalosporin that has previously been used as a primary screen. Most commercial systems are validated for E. coli and K. pneumoniae only. They are not ideal for detecting ESBLs in the presence of AmpC b-lactamases (inducible in Enterobacter, Citrobacter, Morganella and Serratia spp.; hyper-produced in E. coli and acquired in K. pneumoniae and other species) as these enzymes may be induced by clavulanic acid and may then attack the indicator cephalosporin, masking the inhibition of any co-present ESBL. Resistance to cefoxitin has been used as a marker for the production of AmpC b-lactamases, but some AmpC types are susceptible to cefoxitin; further, cefoxitin resistance may also arise due to decreased permeability or to species-specific intrinsic resistance. Other methods for detection of AmpC b-lactamases are time-consuming, do not detect all enzymes and cannot be incorporated into routine use. A further approach to detecting ESBLs in the presence of AmpC b-lactamases is to use AmpC-stable fourth-generation cephalosporins such as cefepime or cefpirome, 4 but this generally necessitates prior identification of the organism.
The aim of this study was to devise a single-plate, disc diffusion method for the detection of ESBLs and AmpC b-lactamases (derepressed and inducible), alone and in combination, in unidentified isolates of Enterobacteriaceae.
Materials and methods
Consecutive, non-replicate isolates of Enterobacteriaceae that were resistant to cefpodoxime (urinary isolates, n ¼ 74) or ceftazidime and/or cefotaxime (systemic isolates, n ¼ 66) were collected from The Royal Hallamshire Hospital, Sheffield (January 2008-March 2008). They were identified by standard agar incorporation methods 6 and comprised E. coli (39 urinary, 13 systemic), Enterbacter agglomerans (14/9), E. cloacae (6/11), C. freundii (6/10), M. morganii (3/4), Enterobacter aerogenes (1/5), Klebsiella oxytoca (1/5), K. pneumoniae (1/5), S. marcescens (3/2), Hafnia alvei (0/1) and Providencia alcalifaciens (0/1). AmpC b-lactamase gene pools (MOX-1, MOX-2, CMY-1, CMY-8 to CMY-11; LAT-1 to LAT-4, CMY-2 to CMY-7, BIL-1; DHA-1, DHA-2; ACC; MIR-1T, ACT-1; FOX-1 to FOX-5b) were sought in the 140 clinical isolates by PCR using the method of Pérez-Pérez and Hanson 7 with the exception that 4.5 mL of overnight culture was used instead of 1.5 mL. SHV-and TEM-derived ESBL genes were sought using the PCR methodology of Naiemi et al., 8 and CTX-M genes were sought by the method of Bouallègue-Godet et al. 9 Resistances due to K1
b-lactamase, hyper-production of b-lactamase and impermeability were discerned by interpretative reading. 10 Genotypically characterized culture collection strains (n ¼106) 10 were also included in the study as were 34 characterized isolates kindly supplied by Dr Mandy Wootton, University Hospital of Wales. Together, these comprised E. coli (55), K. pneumoniae (35), E. cloacae (17), K. oxytoca (14), E. aerogenes (7), Proteus mirabilis (5), E. agglomerans (3), C. freundii (3) and M. morganii (1).
Isolates were processed in a blinded fashion with PCR for ESBL genes, PCR for AmpC genes and disc diffusion carried out at different centres. Disc diffusion tests were carried out according to BSAC methodology 11 using paired discs prepared to FDA limits. Briefly, cefpodoxime discs (10 mg)+clavulanate (Mast Diagnostics, Derby Road, Bootle, UK) and cefepime discs (30 mg)+clavulanate were applied using a standard disc dispenser. A cefoxitin disc (30 mg) was then applied by forceps so that it was 15 mm (centre-to-centre) from the cefpodoxime and cefpodoxime/clavulanate discs that were adjacent to each other. After overnight incubation, zone diameters were read using a MastascanElite automated reader (Mast Diagnostics). Zone diameters were entered into Microsoft Excel and the difference in zone diameters between cefpodoxime/clavulanate and cefpodoxime, cefepime/clavulanate and cefepime, and cefepime/clavulanate and cefpodoxime/clavulanate was calculated. Blunting of the cefpodoxime+clavulanate zones by cefoxitin was also noted. 5), H. alvei (1), K. oxytoca (1), K. pneumoniae (1), P. alcalifaciens (1)]; ESBL þ AmpC [n ¼32: E. cloacae (11), E. agglomerans (7), E. aerogenes (4), E. coli (4), C. freundii (3), K. pneumoniae (2), P. mirabilis (1); neither (n ¼ 31). Phenotypically, AmpC genes were inducible on 30 occasions (5 in the presence of an ESBL), and the majority of these (24) were found in clinical isolates. All six AmpC pools were detected overall. Of the 31 isolates not displaying ESBL or AmpC genes, 5 were thought to be hyper-producers of b-lactamase (K. pneumoniae), 12 were impermeable (E. coli) and 14 harboured K1 b-lactamase (K. oxytoca).
Results and discussion
All 117 ESBL-producing strains (together with 5 in the presence of an inducible AmpC) gave a cefpodoxime/clavulanate zone diameter of .5 mm greater than the corresponding cefpodoxime zone diameter (Figure 1a) . Isolates producing an AmpC b-lactamase (derepressed or inducible) and those producing neither an AmpC b-lactamase nor an ESBL produced a zone difference of 5 mm as did those producing both an ESBL and an AmpC b-lactamase. This highlights the deficiency in using cefpodoxime+clavulanate for the detection of ESBLs in the presence of AmpC b-lactamases.
Using a similar strategy with cefepime/clavulanate and cefepime discs, 25 ESBL-producing isolates would have been missed and this emphasizes the fact that these discs cannot be recommended as a single screen for ESBLs in Enterobacteriaceae. However, their strength lies in the fact that the combination can detect ESBLs in the presence of AmpC b-lactamases (all 32 isolates detected; Figure 1b) . In a survey of 32 027 consecutive clinical isolates of Gram-negative bacteria, we showed that 24% A breakpoint of .14 mm between cefepime/clavulanate and cefpodoxime/clavulanate zone diameters differentiated AmpC b-lactamase producers (alone or in the presence of an ESBL) from the remaining organisms (Figure 1c) . The presence of an inducible AmpC b-lactamase was discerned by observing the blunting of the cefpodoxime or cefpodoxime/clavulanate zone by cefoxitin. Extended-spectrum AmpC b-lactamases, characterized by increased catalytic activity against oxyimino-cephalosporins including cefepime, were not detected in this study. Nonetheless, isolates resistant to cefepime would merit further study.
The strategy for examination of isolates is thus: screen with cefpodoxime or with cefotaxime and/or ceftazidime and then test any resistant isolates with the five-disc combination. The method may also be used to provisionally detect resistant organisms in blood cultures yielding Gram-negative bacteria or as a follow-up for isolates initially tested by automated methods. The use of five discs in this configuration permits two further discs to be added to the plate and these may be antibiotics used for specific treatment of resistant organisms, e.g. carbapenems (meropenem or ertapenem), temocillin or fosfomycin.
There is clearly a need for a simple test to discern ESBL-producing organisms and AmpC-b-lactamase-producing organisms. For example, UKNEQAS distribution 2355 (25 August 2008) was an E. coli that produced a plasmid-mediated AmpC b-lactamase; however, 24% of participants incorrectly reported that the organism was an ESBL producer (Christine Walton, personal communication). 
